drugset
drugset / Trial / NCT00555399

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

NCT00555399 ↗

Phase 1/2 Terminated 55 enrolled M.D. Anderson Cancer Center Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if vorinostat when given with isotretinoin and temozolomide can help to control glioblastoma or gliosarcoma. The safety of these drug combinations will also be studied.

Timeline

Start
2007-11-28
Primary completion
2020-01-24
Completion
2020-01-24

Outcome

Outcome not reported

Stopped (Business): “No Sponsor funding for continuation of trial”

Drugs

EvaluationDrugModalityDoseRoute
Subject Isotretinoin Other / unclassified 100 mg/m2 Oral
Subject Temozolomide Small molecule 100 mg/m2 Oral
Subject Temozolomide Small molecule 125 mg/m2 Oral
Subject Temozolomide Small molecule 150 mg/m2 Oral
Subject Vorinostat Small molecule 300 mg Oral
Subject Vorinostat Small molecule 400 mg Oral
Subject Vorinostat Small molecule 500 mg Oral

Indications

glioblastoma